临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Mometasone Furoate Hydrate
中文名称:(8S,9R,10S,11S,13S,14S,16R,17R)-9-氯-17-(2-氯乙酰基)-11-羟基-10,13,16-三甲基-3-氧代-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊二烯并[a]菲-17-基呋喃-2-羧酸酯水合物
CAS号:141646-00-6
分子式: C27H30Cl2O6.H2O 分子量: 633.51
产品形式: Monohydrate
研发状态: Completed
研发用途: Chronic Sinusitis
研究机构: Lyra Therapeutics
研发日期: June 6 2017
研发阶段: Phase 1
Mometasone Furoate (SCH 32088) Hydrate is a synthetic glucocorticoid with anti-inflammatory activity.
Dronedarone
中文名称:决奈达隆
CAS号:141626-36-0
分子式: C31H44N2O5S 分子量: 556.76
产品形式: Free Base
研发状态: Unknown status
研发用途: ICD; ICD SHOCKS; DRONEDARONE
研究机构: Rabin Medical Center
研发日期: Oct-11
研发阶段: Not Applicable
Dronedarone (SR33589) is a derivative of amiodarone which is classified as a Class III antiarrhythmic agent. It shows rate-dependent inhibition of the rapid Na+ current, inhibits α and β-adrenergic receptors like Class II agents, exhibits blockade of K+ outward currents as the main mechanism of action of Class III, and effectively block slow Ca2+ inward currents (Class IV).
Dronedarone HCl
中文名称:盐酸决奈达隆
CAS号:141625-93-6
分子式: C31H44N2O5S.HCl 分子量: 593.22
产品形式: HCl
研发状态: Unknown status
研发用途: ICD; ICD SHOCKS; DRONEDARONE
研究机构: Rabin Medical Center
研发日期: Oct-11
研发阶段: Not Applicable
Dronedarone HCl (SR33589) is a multichannel blocker targeting potassium channel, sodium channel and calcium channel, used as an antiarrhythmic drug for treatment of atrial fibrillation (AF).
Evobrutinib (M-2951)
中文名称:依伏替尼
CAS号:1415823-73-2
分子式: C25H27N5O2 分子量: 429.51
产品形式: Free Base
研发状态: Completed
研发用途: Healthy
研究机构: Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
研发日期: January 13 2022
研发阶段: Phase 1
Evobrutinib (M-2951, MSC-2364447C) is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity.
M7583
CAS号:1415823-49-2
分子式: C25H26FN5O2 分子量: 447.51
产品形式: free base
研发状态: Recruiting
研发用途: Myelofibrosis; Primary Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis
研究机构: Telios Pharma Inc.
研发日期: June 9 2022
研发阶段: Phase 1 : Phase 2
M7583 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with IC50 and Ki of 1.5 nM and 11.9 nM, respectively.
Crizotinib hydrochloride
中文名称:克里唑替尼盐酸
CAS号:1415560-69-8
分子式: C21H23Cl3FN5O 分子量: 486.80
产品形式: Hydrochloride
研发状态: Not yet recruiting
研发用途: Non-Small Cell Lung Cancer
研究机构: Han Xu M.D. Ph.D. FAPCR Sponsor-Investigator IRB Chair; Medicine Invention Design Inc
研发日期: March 28 2024
研发阶段: Phase 2 : Phase 3
Crizotinib (PF-02341066) hydrochloride (Xalkori) inhibits tyrosine phosphorylation of c-Met and nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) with IC50 of of 11 nM and 24 nM in cell-based assays, respectively. Crizotinib hydrochloride is also a potent ROS1 inhibitor with Ki less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
